Skip to content

Rehabilitation for People With Advanced Cancer

Project 3 - Phase II, Preference Based, Randomized Controlled Trial of Group-Based, In Person Versus Virtual, Cancer Rehabilitation for People With Metastatic / Advanced Breast or Colorectal Cancers

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05424068
Enrollment
111
Registered
2022-06-21
Start date
2022-12-02
Completion date
2026-01-16
Last updated
2026-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Breast Cancer, Advanced Colorectal Cancer, Cancer Rehabilitation

Keywords

Cancer Rehabilitation, Virtual Cancer Rehabilitation

Brief summary

The proposed study is a Phase II, feasibility, randomized controlled preference based study. This will be conducted in Vancouver and Toronto and includes breast and colorectal cancers.

Detailed description

Cancer rehabilitation interventions that address common impairments and focus on maintaining or reducing the rate of functional decline are greatly needed for the growing population of cancer survivors living with incurable or metastatic cancer. In the curative setting, the main gaps in care include lack of referral and barriers to access care; however, in the metastatic setting, high quality evidence on safety, acceptability, and efficacy is still required. In response, based on the results of a need assessments (n=50) of this population and input from palliative care experts, we recently developed the CaRE-Advanced Cancer (CaRE-AC) program. Similar to CaRE@ELLICSR, CaRE-AC is an 8-week multidimensional, group-based program with exercises classes and selfmanagement skills teaching. A single-arm phase I pilot of this program is currently being conducted to assess the feasibility and acceptability (Co-PIs Jones/Langelier). To date, 14 patients have enrolled and 9 patients have completed the program (64%). All participants reported feeling the program was safe and 90% were satisfied with the structure and content. Data collection is expected to be complete be the end of 2019 and the findings will inform revisions to the program format and content. To build on this work, Project Three is a Phase II feasibility RCT of the CaRE-AC program. Results will inform the development of a multicentre pragmatic RCT protocol.

Interventions

BEHAVIORALIn-person rehabilitaiton group

participants who have chosen to complete the study intervention by coming in for their 8 week education and exercise sessions.

BEHAVIORALVirtual rehabilitation group

Participants who have chosen to complete the study virtually instead of in-person sessions.

Sponsors

University Health Network, Toronto
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age 18 years or older * Diagnosed with locally advanced incurable or metastatic breast or colorectal cancer * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 * Fully independent with ambulation and transfers with or without ambulatory assistance * Palliative Performance score of \>70 (moderate predictive power estimating life expectancy \>6 months) * Receiving first or second line anti-cancer treatments in the metastatic / incurable setting (a relative proxy for expected survival \>6 months) * Medical clearance to participate from treating physician

Exclusion criteria

* Wheelchair level community ambulation * Moderate or severe non-cancer pain (\>6 out of 10 on visual analog scale) * Moderate or severe cancer bone pain (\>Gr 2 bone pain (i.e., moderate pain limiting instrumental ALDs or worse) as measured on CTCAE (see below)) * Severe or uncontrolled depressive symptoms (\>20 on PHQ-9) * Known neurological conditions influencing cognition and preventing safe or appropriate engagement with self-management and exercise recommendations (e.g., dementia, traumatic brain injury, or brain metastasis influencing cognition or causing moderate-to-severe motor-sensory-coordination). Best determined by the referring physician or nurse practitioner. * Unable to communicate sufficiently in English to complete intervention, questionnaires, and consent. * Unwillingness to be randomized, participate in a group intervention, or attend individual physical assessments. * Inability to operate videoconferencing if preference is virtual programming.

Design outcomes

Primary

MeasureTime frameDescription
Drop-out rates as a measure of feasibility (demand/update of intervention)6 monthsNumber of patients who complete the study/ drop-out will be used to identify feasibility of the intervention.
Patient preference as assessed during clinical support as a measure of feasibility (acceptability)6 monthsCheck-ins with Kinesiologist during assessments will be used to identify intervention acceptability/preference.
Measuring safety/practicality as assessed during one-on-one with the health coach (analyzed as qualitative data)6 monthsCompleted over MS Teams/in-person and will be a conversational question and answer format.

Secondary

MeasureTime frameDescription
Disability6 monthsMeasured using the 12 item World Health Organization Disability Assessment Schedule 2.0 which is a cross-cultural, standardized method for measuring limitations and restrictions on individuals' activities and participation in society.
Physical functioning6 monthsMeasured using the 10 item physical function subscale of Short-Form Health Survey (scale from 0 (negative health) to 100 (positive health) ).
Social functioning6 monthsMeasured using the Social difficulties Inventory. A 0.0 score indicates perfect comparison with consensus group and \> or equal to 2 indicates unacceptable performance/remedial action required
Depression6 monthsMeasured using the Patient Health Questionnaire. The test is scored on a scale from 0 to 27, with higher scores indicating more severe symptoms.
Anxiety6 monthsMeasured using the Generalized Anxiety Disorder 7. The overall GAD 7 score ranges between 0 and 21, 0 meaning no anxiety and 21 meaning severe anxiety.
Quality of Life for advanced cancer - wellbeing6 monthsMeasured using Functional Assessment of Chronic Illness Therapy-Palliative Care. This is a measure of health-related quality of life for persons with advanced cancer.
Symptom Burden6 monthsMeasured with the 9-item Edmonton Symptom Assessment System. Each symptom is rated from "0 to 10". A score of "0" means you do not have the symptom. A score of "10" means that your symptom is at its very worst.
Safety and Health Care Utilization6 monthsMeasured using a self-report questionnaire. tilization can be measured as the number of services provided to a patient, such as the number of X rays. More often, however, a variety of procedures and services are of interest, and some measure of "cost" is assigned to each service so that resource intensity can be summed over all provided services.
Weekly Session feedback8 weeksFollowing each educational module, participants will be asked to complete a short feedback form of 7-10 questions. Questions will explore participant's feelings surrounding session length, content, presentation quality, and recommendations for improvement. Additional questions for participants in the virtual arm will be included and inquire about video, audio, and presenter quality.
Physiological measure of height6 monthsParticipant height at baseline
Physiological measures of weight6 monthsParticipant weight at all physical assessments (T1, T3, T4, T5, not T2) will be collected. This data will inform calculations for BMI.
Physiological measures of exercise Intensity (Perceived Exertion)6 monthsDuring each exercise class participants will be instructed on the target rated perceived exertion (RPE) goal for that day. The RPE has been found to provide a good estimate of participant heart rate during physical activity54. Following each exercise class, each participants will be asked to provide exercise staff with a RPE score on a scale of 6 (no exertion at all) to 20 (maximal exertion) of effort. Participants who do not achieve the target RPE will be asked to provide a reason (if known).
Physiological measures of total Exercise Participation for sleep6 monthsEach participant will be provided a FitBit® to help track purposeful and leisure time physical activity from time point T1 (program intake) through T4 (3 months post program completion). From those consenting, data pertaining to step count sleep will be downloaded from participant accounts at each time point (T2, T3, and T4).
Physiological measures of total Exercise Participation for step count6 monthsEach participant will be provided a FitBit® to help track purposeful and leisure time physical activity from time point T1 (program intake) through T4 (3 months post program completion). From those consenting, data pertaining to step count will be downloaded from participant accounts at each time point (T2, T3, and T4).
Physiological measures of total Exercise Participation for heart rate.6 monthsEach participant will be provided a FitBit® to help track purposeful and leisure time physical activity from time point T1 (program intake) through T4 (3 months post program completion). From those consenting, data pertaining to heart rate will be downloaded from participant accounts at each time point (T2, T3, and T4).
Physiological measures of cardiorespiratory fitness6 monthsMeasured with the six minute walk test (6MWT)
Physiological measures of muscular strength6 monthsMeasured with hand grip strength for upper body
Physiological measures of endurance6 monthsMeasured with 30-second sit to stand test for lower body strength
Physiological measures of balance6 monthsMeasured with the Balance test
Physicial activity6 monthsMeasured using the modified Godin Leisure Score Index (LSI) of the Godin and Shepherd Leisure Time Exercise Questionnaire (GLTEQ)
Physiological measures of Performance6 monthsMeasured with the 4-meter Gait speed test
Quality of Life for advanced cancer - daily life activities6 monthsMeasured using EuroQol 5 dimension. This measure has 5 levels, with level 1 indicating no problems and level 5 indicating extreme problems
Demographics6 monthsDemographic details will be collected from participants at the time of initial assessment via an intake questionnaire. There are no scales, only patient reported outcome questions.

Countries

Canada

Contacts

PRINCIPAL_INVESTIGATORJennifer Jones, PhD

University Health Network, Toronto

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 27, 2026